Ehrlichiosis in Dogs: A Comprehensive Review for Small Animal Practitioners -By Dr. Hassan Shuaibu, DVM

ABSTRACT

Ehrlichiosis is a tick-borne infectious disease of significant clinical importance in canine populations attending veterinary clinics in tropical and subtropical regions, including West Africa. This article provides a comprehensive review of Ehrlichia canis as the causative agent of canine ehrlichiosis, examining epidemiology, pathophysiology, clinical presentation, diagnostic approaches, and therapeutic management relevant to small animal practice. The disease presents with highly variable clinical manifestations across acute and chronic phases, necessitating systematic diagnostic and clinical evaluation. Doxycycline-based antimicrobial therapy remains the standard of care, with treatment protocols tailored to disease phase and severity. This review aims to enhance clinical recognition and management of ehrlichiosis among veterinary practitioners in West Africa and similar regions, supporting improved diagnostic accuracy and treatment outcomes in companion animals presenting to veterinary clinics.

Keywords: Ehrlichia canis, canine ehrlichiosis, tick-borne disease, diagnosis, treatment, small animal practice, West Africa

1. INTRODUCTION

Ehrlichiosis is a rickettsial disease affecting dogs that is caused primarily by Ehrlichia canis, an obligate intracellular bacterium transmitted by the brown dog tick (Rhipicephalus sanguineus). The disease has gained increasing clinical significance in tropical and subtropical veterinary practice, where favorable environmental conditions support tick vector populations throughout the year. In West Africa, including Nigeria, ehrlichiosis represents a notable clinical entity affecting companion dogs presenting to veterinary clinics with diverse clinical presentations.

The clinical importance of ehrlichiosis for the small animal practitioner extends beyond recognition of acute disease presentations. Dogs frequently present with chronic or subclinical manifestations that may be attributed to other causes if ehrlichiosis is not considered in the differential diagnosis. The highly variable clinical expression, ranging from inapparent infection to severe systemic disease, requires systematic diagnostic evaluation and clinical acumen. Early and accurate diagnosis facilitates appropriate treatment and improves clinical outcomes.

This article examines ehrlichiosis in dogs through comprehensive analysis of current literature, disease pathophysiology, clinical manifestations, and diagnostic methodologies. The review emphasizes practical approaches to diagnosis and management relevant to small animal practitioners and veterinary clinicians.

2. LITERATURE REVIEW

2.1 Etiology and Epidemiology

Canine ehrlichiosis is caused by Ehrlichia canis, a gram-negative, obligate intracellular rickettsia belonging to the family Anaplasmataceae. The disease is transmitted by the brown dog tick (Rhipicephalus sanguineus), which is widely distributed across tropical and subtropical regions and is particularly prevalent in warm climates. Secondary transmission through blood transfusions and transplacental transmission have been documented but are considered minor routes of infection.

Geographic distribution of canine ehrlichiosis extends across tropical and subtropical zones, with endemic foci in Mediterranean regions, the Middle East, Africa, and parts of Asia. The disease is now recognized in sub-Saharan Africa, though epidemiological data from many African countries remain incompletely characterized. In endemic areas, seroprevalence studies indicate infection rates ranging from 5% to 60% depending on geographic location, tick exposure, and diagnostic methodology employed.

Risk factors for ehrlichiosis include exposure to infected tick vectors, age (with reports of variable age-related susceptibility), immune status, and concurrent parasitic or infectious conditions. Dogs with subclinical infection may remain in this phase indefinitely, while others progress to clinical disease manifestations months or years after initial infection.

2.2 Pathophysiology

Following tick transmission, Ehrlichia canis establishes infection by invading circulating monocytes and macrophages. The organism replicates within membrane-bound vacuoles, effectively evading many innate immune mechanisms. The pathogenic process involves several key mechanisms:

Inflammatory response: Infected monocytes release pro-inflammatory cytokines, initiating systemic inflammation manifesting as fever, anorexia, and malaise.

Bone marrow suppression: Ehrlichia organisms or inflammatory mediators damage hematopoietic tissue, resulting in thrombocytopenia (the most characteristic finding), anemia, and sometimes leukopenia.

Vasculitis: Endothelial inflammation may lead to platelet consumption, vascular leak, hemorrhage, and coagulopathy.

Chronic infection, if untreated, may result in persistent immune stimulation, hypergammaglobulinemia, and immune complex deposition in tissues, contributing to glomerulonephritis and systemic vasculitis.

2.3 Clinical Manifestations

Canine ehrlichiosis classically occurs in three phases: acute, subclinical, and chronic. However, clinical presentation is highly variable; dogs may progress through all phases, remain in subclinical carrier status indefinitely, or display only acute or chronic disease manifestations.

Acute Phase (1–3 weeks post-infection): Clinical signs include fever (39.5–40.5°C), lethargy, anorexia, and exercise intolerance. Lymphadenopathy and mild splenomegaly may be present on physical examination. Gastrointestinal signs (diarrhea, vomiting) and mild respiratory signs can occur. Notably, many acutely infected dogs may show no clinical signs or only subtle clinical changes, facilitating subclinical progression.

Subclinical Phase: Dogs harbor infection without overt clinical manifestations, detectable only through serological testing or PCR. Duration is variable, ranging from weeks to years. Dogs may remain in this phase indefinitely or progress to chronic disease.

Chronic Phase (weeks to years): Persistent infection manifests as generalized malaise, weight loss, pale mucous membranes indicative of anemia, and bleeding tendencies (petechiae, ecchymoses, epistaxis, hematuria). Lymphadenopathy and splenomegaly are common. Ocular manifestations including anterior uveitis, keratitis, and chorioretinitis may occur. Secondary complications include polyarthritis, glomerulonephritis, and systemic vasculitis.

3. CLINICAL PRESENTATION AND DIAGNOSIS

3.1 Clinical Assessment in Small Animal Practice

Dogs presenting to veterinary clinics with ehrlichiosis display a wide spectrum of clinical signs. Common presenting complaints include lethargy, anorexia, fever of unknown origin, pale mucous membranes, bleeding manifestations, or signs of systemic illness unresponsive to initial empirical therapy.

Physical examination findings frequently include fever, generalized or localized lymphadenopathy, and pale mucous membranes in chronic cases reflecting anemia. Bleeding manifestations such as petechiae on mucous membranes, bleeding from gums, or spontaneous bleeding warrant immediate attention and suggest severe thrombocytopenia. Ocular examination may reveal anterior uveitis or retinal changes. Abdominal palpation may reveal hepatomegaly or splenomegaly.

A thorough history should include tick exposure, geographic location, vaccination and preventive medication status, duration of clinical signs, and response to any previous treatments. Knowledge of ehrlichiosis prevalence in the local region assists in clinical reasoning.

3.2 Diagnostic Approaches

Hematology: Complete blood count (CBC) is the most practical initial diagnostic test. Thrombocytopenia (<50,000/μL) is the most consistent finding and is often the first abnormality detected. Anemia of chronic disease and leukopenia may also be present. Examination of blood smears may occasionally reveal Ehrlichia morulae within circulating monocytes during acute infection, though sensitivity is low (approximately 5%).

Serology: Indirect fluorescent antibody (IFA) testing or ELISA detects anti-Ehrlichia IgG antibodies. A single positive titer indicates exposure or infection but does not differentiate between active infection and past exposure. Paired acute and convalescent sera collected at 2–4 week intervals showing a four-fold or greater titer rise confirm recent or active infection. Cross-reactivity with other Anaplasmataceae species may occur depending on the test platform.

PCR: Real-time PCR detection of Ehrlichia DNA in blood is the most specific diagnostic modality and is useful particularly during acute infection and early chronic phase. Sensitivity may decrease in chronic carriers with low levels of bacteremia. PCR is valuable for confirmation and species identification when available.

Biochemistry: Serum chemistry panels may reveal elevated alkaline phosphatase, ALT, and urea suggesting hepatic and renal involvement. Hypoalbuminemia and hypergammaglobulinemia have been reported in chronic cases. Positive rheumatoid factor may be detected in some chronically infected dogs.

Practical Diagnostic Approach: In resource-limited settings or areas where sophisticated diagnostics are unavailable, clinical presentation combined with CBC findings (thrombocytopenia with compatible clinical signs) in a tick-exposed dog warrants empirical doxycycline therapy. Clinical response within 48–72 hours (fever resolution, improved appetite) supports ehrlichiosis diagnosis.

4. TREATMENT AND CLINICAL MANAGEMENT

4.1 Antimicrobial Therapy

Doxycycline is the antimicrobial of choice for ehrlichiosis. The standard dosage is 10 mg/kg administered orally twice daily for 28 days in acute infection. For chronic cases, treatment duration is typically extended to 4–6 weeks, with some clinicians recommending up to 6–8 weeks in severe or complicated cases. Doxycycline crosses intracellular compartments effectively and achieves therapeutic concentrations within monocytes, the primary target cells for Ehrlichia canis.

Clinical response to doxycycline is typically favorable in acute cases, with resolution of fever and improved appetite occurring within 48–72 hours of treatment initiation. Thrombocytopenia gradually resolves over 1–3 weeks of therapy. Some chronically infected dogs may harbor persistent organisms despite appropriate antimicrobial therapy; in such cases, periodic testing and extended or repeated treatment courses may be necessary.

Alternative antimicrobials have been evaluated, including tetracycline and minocycline, though doxycycline remains the preferred agent due to superior bioavailability and tissue penetration. In cases of doxycycline intolerance, fluoroquinolones (e.g., enrofloxacin) may be considered as alternatives, though clinical efficacy data are limited. Macrolides are not recommended due to inadequate intracellular penetration.

4.2 Supportive and Symptomatic Care

Supportive care is essential in managing ehrlichiosis, particularly in severely affected animals. In cases of severe anemia (hemoglobin <5 g/dL), whole blood or packed red blood cell transfusion may be indicated. Fluid therapy supports hydration status, particularly in animals with gastrointestinal involvement or systemic manifestations.

Nutritional support with high-quality, easily digestible food enhances recovery in debilitated animals. Monitoring for and management of secondary infections is important. Corticosteroids may be indicated in severe immune-mediated manifestations such as immune-mediated thrombocytopenia or severe vasculitis, but should be used cautiously given the inherent immunosuppressive nature of ehrlichiosis. Pain management with appropriate analgesics is warranted in animals with polyarthritis or other painful complications.

4.3 Prevention and Client Education

Tick control is the cornerstone of ehrlichiosis prevention. Practitioners should counsel dog owners on the use of effective ectoparasiticide products, including pyrethroids, organophosphates, imidacloprid, fipronil, and other acaricides effective against Rhipicephalus sanguineus. Regular application according to product instructions is essential for maintaining protection.

Client education regarding ehrlichiosis recognition, clinical signs, and the importance of prompt veterinary consultation enhances early case detection. Dogs with known tick exposure presenting with fever, lethargy, or thrombocytopenia should be evaluated for ehrlichiosis. Screening of donor dogs prior to blood transfusion and consideration of testing breeding animals in endemic areas is prudent.

5. CONCLUSION

Ehrlichiosis is an important infectious disease affecting companion dogs in West Africa and other tropical/subtropical regions. The highly variable clinical presentation—ranging from inapparent infection to severe systemic disease—requires that ehrlichiosis be included in the differential diagnosis of dogs presenting with compatible clinical signs and tick exposure history. Systematic diagnostic evaluation combining physical examination, CBC findings, and serological or PCR testing enables accurate diagnosis. Early recognition and appropriate doxycycline-based therapy yield favorable clinical outcomes in most cases.

For small animal practitioners in West Africa, maintaining a high index of suspicion for ehrlichiosis in appropriate clinical contexts is essential. Practical diagnostic approaches utilizing readily available tests (CBC, serology) facilitate case confirmation in resource-limited settings. Improved awareness of ehrlichiosis among veterinary professionals supports timely diagnosis, appropriate treatment, and ultimately improved health outcomes for affected dogs.

Dr. Hassan Shuaibu, DVM [UNIMAID]